^
BIOMARKER:

KMT2D mutation

i
Other names: KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10




Show legend

Include preclinical:
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Diffuse Large B Cell Lymphoma
Cervical Cancer
Colorectal Cancer
Chronic Lymphocytic Leukemia
Lung Cancer
Follicular Lymphoma
Marginal Zone Lymphoma
Triple Negative Breast Cancer
durvalumab + tremelimumab
ibrutinib
anlotinib + sintilimab
Immunotherapy
cyclophosphamide + epirubicin
PD1 inhibitor
zanubrutinib
decitabine
chidamide
ibrutinib + chidamide
ibrutinib + decitabine
afatinib + SHP099
R-CHOP